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Sunday, February 26, 2012 61ascreening methods, considers the protein conformation change upon binding by
using two different protein conformations and also takes into account the sol-
vation effect by including conserved water molecules in the active site. The top
ranked molecules from each pharmacophore hypothesis are further analyzed
according to their interactions with AKT-2 and the ultimate docking results
from Glide are compared with previously identified inhibitors based on struc-
ture and chemistry.
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Stable Complexes of LYN Kinase and Druglike Small Molecules
D.S. Dalafave.
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Glioblastoma multiforme (GBM) is a very aggressive brain cancer in humans.
Even with improvements in surgical, radiation, and chemotherapy treatments,
current prognosis is bleak, with only a 14-month median survival time. LYN,
an important kinase involved in cell regulation, is often overexpressed in
GBM. This work addresses computational design of druglike small molecules
that could potentially inhibit LYN and thus hinder GBM progression. New pu-
tative LYN inhibitors were obtained by atomic substitutions and structural
alterations of bafetinib, a small molecule previously found to bind LYN. Drug-
like properties and toxicities of the designed molecules were evaluated using
the Osiris Property Explorer program. Molecules with no implied toxicities
and most favorable druglike properties were used for docking studies in the
ArgusLab program. Designed molecules that made the most stable docking
configurations with LYN, but no stable configurations with other kinases,
were identified as LYN-specific. Binding energies of the stable complexes
formed by these molecules and LYN were calculated. Possible utilization of
the designed molecules in drug research against GBM is discussed.
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As part of our effort to understand the determinants of drug binding to the Abl
tyrosine kinase, we determined the crystal structure of the Abl kinase domain
bound to a derivative of the PP1 nucleoside analog. Just as the cancer drug im-
atinib selectively inhibits the tyrosine kinase activity of c-Abl, c-Kit, and the
PDGF receptor, but is a poor inhibitor of the closely related Src kinases (1),
PP1 is a selective inhibitor of the Src family (2), c-Kit (3), and PDGFR kinases
but not of Abl tyrosine kinase activity (3, 4). In fact, PP1 is 1000X less effective
at inhibiting Abl and Bcr-Abl kinases than at inhibiting the Src kinases (3, 4).
We rationally designed a derivative of the PP1 compound to introduce hydro-
gen bonding between it and a strictly conserved lysine residue that coordinates
the alpha and beta phosphate groups of ATP in protein kinases (5). By expand-
ing the interactions between the inhibitor and Abl kinase, we sought to make
the PP1 derivative, AB129, less selective. Our crystal structure of the Abl ki-
nase domain bound to the AB129 inhibitor shows three important features.
First, the compound binds to the kinase domain in the active conformation: al-
pha C helix is rotated inward facilitating a salt bridge between Lys271 and
Glu286 and the conserved Asp-Phe-Gly (DFG) motif is oriented Asp-In. In
contrast, the structure of PP1 bound to the Src family kinase Hck is in the in-
active conformation (6). Second, the strictly conserved Glu286 residue, not
Lys271, hydrogen bonds to the hydroxyl group of AB129. Third, the conforma-
tion of the phosphate binding loop (P-loop) is extended. We provide kinetic and
calorimetric data to support our rationale for the observed conformational
changes.
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The uncontrolled kinase activity of the oncogenic protein Bcr-Abl is a hall-
mark of Chronic myelogenous leukemia (CML). Although the drug imtanib
is highly effective at shutting down aberrant Abl kinase activity, some
CML patients harbor additional mutations in their bcr-abl gene that renders
their gene product, the Bcr-Abl protein, resistant to this drug. Since secondgeneration Abl kinase inhibitors such as dasatinib are effective only against
particular resistant mutant proteins, new targeted agents are needed to combat
drug resistance. Two combi-inhibitors ZRF1 and ZRF2, which block Bcr-Abl
activity and damage DNA in the cell, have been shown to be more potent than
imatinib in cellular assays. Since both ZRF1 is hydrolyzed in the cell to ZRF0,
an imatinib analog in which only the mono-substituted benzamide piperazinyl
moiety is replaced with bi-substituted amino and trifluoromethyl groups, we
wondered why these two changes had such a profound effect on the potency
of the drug. To determine whether ZRF1/2’s increased potency was due to the
DNA damaging agent attached to the parent compounds, we sought to co-
crystallize the Abl kinase domain with these two inhibitors at room tempera-
ture and 4C using commercially available sparse-matrix screens. We
screened over 400 crystallization conditions, with Abl and ZRF1, ZRF2, or
dasatinib inhibitors but were unable to obtain crystals of either the Abl-
ZRF1 or Abl-ZRF2 drug complex. Protein crystals in wells containing the
Abl kinase domain and dasatinib, however, were evident in every tray. Since
ZRF1 and ZRF2 are hydrolyzed in the cell, future co-crystallization studies of
Abl and its mutant proteins will employ the hydrolyzed inhibitor analogs as
the ligand.
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The large and growing body of experimental data on biomolecular binding is of
enormous value in developing a deeper understanding of molecular biology, in
developing new therapeutics, and in various molecular design applications.
However, most of these data are found only in the published literature and
are therefore difficult to access and use. BindingDB is a public web-
accessible database of measured binding affinities for various molecular types.
The BindingDB allows queries based upon a range of criteria, including chem-
ical similarity or substructure, sequence homology, numerical criteria and reac-
tant names. The data specification includes significant experimental detail. The
time and expense required to extracting data from the literature, for this and
many other databases, highlight the importance of moving toward machine-
readable components of publications.
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Protein-ligand docking techniques are one of the essential tools for structure-
based drug design. Although conformational changes of protein receptor fre-
quently occur in the binding process, a large fraction of contemporary docking
programs ignore receptor flexibility. Consideration of protein flexibility effi-
ciently and accurately in docking studies is challenging due to difficulties in
finding accurate scoring function and in sampling conformations efficiently.
Previously we developed a docking program called LigDockCSA which incor-
porates LigDock scoring function that combines AutoDock3 and PLP scoring
function and conformational space annealing (CSA) as a sampling method.
However, the program treats protein rigid. Here, we present GALAXYDock,
an extension of LigDockCSA that accounts flexibility of pre-selected side-
chains of receptor protein in the binding site. To test the performance of the
new docking method, 3 sets of protein-ligand complexes that share similar
backbone structures but have different side chain conformations were selected
as test sets: HIV-PR, LXRb and cAPK. The cross-docking results show that the
accuracy of binding pose prediction is increased about 20% when compared
with our previous rigid-receptor results.
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The study of the binding and effects of polyaromatic hydrocarbons (PAH) to
proteins remains one of the fundamental aspects of research in biophysics.
Among other processes, ligand binding can regulate the function of proteins in-
cluding inhibiting their action. Binding to small ligands remains a very im-
portant aspect in the study of the function of many proteins. We studied
a new class of 3,9-substituted perylene derivatives designed to optimize
62a Sunday, February 26, 2012electron donating properties that would optimize photoinduced electron trans-
fer (PET) from the ligand to the protein and prompt charge-induced conforma-
tional changes.
Our study focuses on the interaction of four 3,9-substituted perylenes with Hu-
man Serum Albumin (HSA), which is the prime protein model for the binding
of PAH. We present docking simulation results for possible sites for the pery-
lenes within HSAwith the lowest free energy of binding and correlate the dock-
ing simulations with fluorescence result. Docking simulations reveal that all the
peylen derivatives bind at the core of HSA and that the dimethoxy derivative
has larger affinity than the other perylenes. Docking seems to be stabilized
by aromatic interactions with Tyr and Trp groups.
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Calmodulin (CaM) is a calcium-binding protein that mediates signal transduc-
tion through an ability to differentially bind to highly variable binding
sequences in target proteins. Experimental measurements show a linear corre-
lation between conformational entropy and overall binding entropy, suggesting
that a predictive ability to calculate conformational entropy is critical to the
identification of binding partners and their relative affinities. To identify
how binding affects low- and high-frequency motions, and their relationships
to conformational entropy, we have employed fully atomistic molecular dy-
namics simulations with explicit solvent. The calculated quasiharmonic entro-
pies of CaM bound to the targets relative to unbound CaM are in agreement
with experimentally derived conformational entropies, where extrapolation
to infinite simulation time showed that at least 92% of the backbone entropy
is captured over the course of the 100 ns simulation. Enhanced side chain en-
tropy results from conformational disruption of the protein backbone within
loop regions between sub-domain elements, acting to facilitate the formation
of transient salt bridges between Lys148 at the C-terminus and GLU sidechains
both in CaM helix A and GLU side-chains present in selected binding se-
quences (i.e., endothelial and neuronal nitric oxide synthases). Comparison
of Ca root-mean-squared fluctuations and MET sidechain dihedral distribu-
tions of CaM bound to each of the targets revealed that MET sidechains
have more torsional freedom when the backbone is more flexible, showing
that MET sidechain rotation mirrors the overall conformational binding en-
tropy. Taken together, these results help to illuminate the interplay between
electrostatic, hydrophobic, backbone and sidechain properties in the ability
of CaM to recognize and discriminate against targets by tuning its conforma-
tional entropy.
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Lactate Dehydrogenase (LDH) catalyzes the interconversion of pyruvate and
lactate with concomitant interconversion of NADH and NADþ. Due to the
widespread presence in a variety of organisms, LDH has been served as a gen-
eral model for studying the catalytic mechanism of enzymes. Extensive IR
spectroscopic studies by Callender et al. have revealed complex conformational
sub-states for different substrate binding to LDH in mesophilic and thermo-
philic organisms. To facilitate the elucidation of the underling mechanism of
LDH enzyme reaction, molecular dynamics simulation approaches were ap-
plied to study the conformational dynamics of mesophilic LDH in complex
with substrate or its mimics. The functionally important motions were charac-
terized by conformational sampling. To determine the relationship between
protein stability, flexibility, and catalytic activity, thermophilic LDH enzyme
will be further investigated. The energy landscape within the Michaelis com-
plex will be explored. The computational study in connection with the experi-
mental findings will shed new light on the mechanism of enzyme dynamics and
function.
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Abstract: Hepatitis C Virus (HCV) is a major health concern; the virus infects
270-300 million people worldwide. The large number of people infected has
spurred efforts to identify small molecules that may be effective in treating
HCV infection. One of the targeted viral enzymes in these efforts is the viralRNA Dependent RNA polymerase (NS5B) that plays a vital role in replicat-
ing the HCV genome. Several allosteric inhibitors are known to bind to NS5B
in the thumb, fingers and palm domains of the enzyme. Our goal is to under-
stand the mechanism of allosteric inhibition in NS5B using molecular dy-
namic simulations. We are particularly interested in ligand AG6 that has
been shown to bind to the fingers domain. Relatively few allosteric inhibitors
are known to bind to this region of the protein. Studying allosteric inhibiton
involving this uncommon binding site has led to new insights into the mech-
anisms of allostery in NS5B. Moreover, crystallographic data indicate that
NS5B can bind simultaneously to AG6 and another allosteric inhibitor in
the thumb domain. This has given us an opportunity to learn what mecha-
nisms underlie synergistic binding of multiple allosteric inhibitors to the en-
zyme. We used molecular dynamic simulations to understand how changes in
the free energy landscape of NS5B mediate the allosteric effects of inhibitor
binding.
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We present the physicochemical basis of binding for several active peptides
from the compstatin family against the immune system protein C3. The pep-
tide sequences are tailored to promote enhancement of the structural and phys-
icochemical properties that contribute to binding, including consideration of
the dynamic character of the protein/ligand system. The peptide sequences
are designed using: (i) computational sequence selection and approximate
binding affinity calculations, (ii) molecular dynamics simulations, and (iii) ra-
tional optimization [1–3]. A subset of the new peptides has been tested in
ELISA inhibition assays using human serum, and produced comparable
IC50 values to those of known peptides. The most promising new designs ac-
quire an advantage in that they combine a more optimal balance between hy-
drophobicity, which is important for binding, and polarity, which is important
for solubility, compared to the most potent known peptides. Thus, the new
peptides are good candidates to become therapeutics, upon further optimiza-
tion. Given the species specificity of known compstatin family peptides for pri-
mate but not for non-primate mammals, some of the new designs aim at
binding to both human and rat C3. The dual specificity design was conducted
using molecular dynamics simulations based on our recent atomic detail model
for compstatin-human/rat binding [3]; however, the efficacy of the new pep-
tides for rat C3 binding and inhibition remains to be seen in experimental as-
says using rat serum.
[1] Bellows et al. 2010. New compstatin variants through two de novo protein
design frameworks, Biophysical Journal 98:2337–2346.
[2] Lo´pez de Victoria et al. 2011. A new generation of potent complement
inhibitors of the compstatin family, Chemical Biology & Drug Design
77:431–440.
[3] Tamamis et al. 2010. Species specificity of the complement inhibitor comp-
statin investigated by all-atom molecular dynamics simulations, Proteins
78:2655–2667.
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Intrinsically disordered proteins (IDPs) function in many important cellular
pathways, and their disruption contributes to many human diseases. IDPs dis-
play minimal if any secondary or tertiary structure in their unbound forms, but
will often fold into ordered structures upon binding. It is believed that the cou-
pling of folding and binding is important in balancing the affinity and specific-
ity of the interaction due to the reduction in conformational entropy of the
residues at the binding interface. Potential mechanisms include induced folding
and conformational selection, which are not mutually exclusive and the pre-
dominant method utilized may be biased by the entropic barrier in coupled fold-
ing and binding. A model system using the transactivation domain of the tumor
suppressor p53 (p53TAD) and its binding partners, the ubiquitin ligases MDM2
and its homologue MDMX, was designed. p53TAD is an IDP that folds when
binding with MDM2/X. The conformational entropy of p53TAD is systemati-
cally varied using mutagenesis and these mutations result in significant and pre-
dictable changes in the binding affinity. This is the first attempt to quantify how
